Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis

Yinlong Zhang, Jingyan Wei, Shaoli Liu, Jing Wang, Xuexiang Han, Hao Qin, Jiayan Lang, Keman Cheng, Yiye Li, Yingqiu Qi, Greg J. Anderson, Saraswati Sukumar, Suping Li, Guangjun Nie

Research output: Contribution to journalArticle

Abstract

Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)1062-1071
Number of pages10
JournalTheranostics
Volume7
Issue number5
DOIs
StatePublished - 2017

Fingerprint

Nanoparticles
Blood Platelets
Neoplasm Metastasis
Neoplasms
cysteinyl-arginyl-glutamyl-lysyl-alanyl
Circulating Neoplastic Cells
Epithelial-Mesenchymal Transition
Platelet Aggregation Inhibitors
Cell Communication
Pharmaceutical Preparations
Phenotype
Therapeutics

Keywords

  • Liposomal nanoparticle
  • Metastatic inhibition
  • Tumor associated platelets
  • Tumor metastasis

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Zhang, Y., Wei, J., Liu, S., Wang, J., Han, X., Qin, H., ... Nie, G. (2017). Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics, 7(5), 1062-1071. https://doi.org/10.7150/thno.17908

Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. / Zhang, Yinlong; Wei, Jingyan; Liu, Shaoli; Wang, Jing; Han, Xuexiang; Qin, Hao; Lang, Jiayan; Cheng, Keman; Li, Yiye; Qi, Yingqiu; Anderson, Greg J.; Sukumar, Saraswati; Li, Suping; Nie, Guangjun.

In: Theranostics, Vol. 7, No. 5, 2017, p. 1062-1071.

Research output: Contribution to journalArticle

Zhang, Y, Wei, J, Liu, S, Wang, J, Han, X, Qin, H, Lang, J, Cheng, K, Li, Y, Qi, Y, Anderson, GJ, Sukumar, S, Li, S & Nie, G 2017, 'Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis', Theranostics, vol. 7, no. 5, pp. 1062-1071. https://doi.org/10.7150/thno.17908
Zhang, Yinlong ; Wei, Jingyan ; Liu, Shaoli ; Wang, Jing ; Han, Xuexiang ; Qin, Hao ; Lang, Jiayan ; Cheng, Keman ; Li, Yiye ; Qi, Yingqiu ; Anderson, Greg J. ; Sukumar, Saraswati ; Li, Suping ; Nie, Guangjun. / Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. In: Theranostics. 2017 ; Vol. 7, No. 5. pp. 1062-1071.
@article{f3037ec5e09a40c4a3e79996df3b2fab,
title = "Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis",
abstract = "Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.",
keywords = "Liposomal nanoparticle, Metastatic inhibition, Tumor associated platelets, Tumor metastasis",
author = "Yinlong Zhang and Jingyan Wei and Shaoli Liu and Jing Wang and Xuexiang Han and Hao Qin and Jiayan Lang and Keman Cheng and Yiye Li and Yingqiu Qi and Anderson, {Greg J.} and Saraswati Sukumar and Suping Li and Guangjun Nie",
year = "2017",
doi = "10.7150/thno.17908",
language = "English (US)",
volume = "7",
pages = "1062--1071",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "5",

}

TY - JOUR

T1 - Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis

AU - Zhang, Yinlong

AU - Wei, Jingyan

AU - Liu, Shaoli

AU - Wang, Jing

AU - Han, Xuexiang

AU - Qin, Hao

AU - Lang, Jiayan

AU - Cheng, Keman

AU - Li, Yiye

AU - Qi, Yingqiu

AU - Anderson, Greg J.

AU - Sukumar, Saraswati

AU - Li, Suping

AU - Nie, Guangjun

PY - 2017

Y1 - 2017

N2 - Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.

AB - Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.

KW - Liposomal nanoparticle

KW - Metastatic inhibition

KW - Tumor associated platelets

KW - Tumor metastasis

UR - http://www.scopus.com/inward/record.url?scp=85014634234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014634234&partnerID=8YFLogxK

U2 - 10.7150/thno.17908

DO - 10.7150/thno.17908

M3 - Article

VL - 7

SP - 1062

EP - 1071

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 5

ER -